T he host innate immune inflammatory response to lipopolysaccharide (LPS) from Gram-negative bacteria is mediated by the recognition of LPS by Toll-like receptor 4 (TLR4) in the context of TLR4-bound its co-receptor MD2 1-3 . TLR4 is unique among the TLRs in that following the recognition of LPS by MD2, two separate 'modes' of signaling can be initiated, each from a distinct cellular compartment that utilizes distinct signaling intermediates, which results in discrete transcriptional programs 4 . Cell-surface TLR4 engages the intracellular adaptors TIRAP (Mal) and MyD88 through interactions with its Toll-interleukin 1 (IL-1) receptor (TIR) domain to activate signaling via the transcription factor NF-κ B and kinases of the MAPK family and subsequent transcription of genes encoding proinflammatory cytokines (e.g., Tnf and Il1b) 5 . A qualitatively distinct signal-transduction cascade is elicited following endosomal translocation of a portion of LPS-bound TLR4-MD2 through an incompletely understood action of the cell-surface co-receptor CD14 6-8 . The TIR domain of endosomal TLR4 engages the adaptor TRAM, which recruits the adaptor TRIF and leads to activation of the kinase TBK1 that leads to phosphorylation of the transcription factor IRF3 and, ultimately, the production of type I interferons (e.g., IFN-β ) 9-12 . In addition, TRIF signaling also activates a second, unique pathway that involves caspase-8 and the kinases RIP1 and RIP3, which leads to caspase-1-independent processing of pro-IL-1β [13] [14] [15] . The kinetics of activation and termination of the separate signal-transduction cascades driven by MyD88 and TRIF are necessarily limited to protect host tissues from excessive inflammation and to re-establish homeostasis. While MyD88-dependent production of cytokines is crucial for the clearance of many bacterial infections 16 , conversely, the production of type I interferons can promote infection in various models by a mechanism that involves a poorly understood immunosuppression 17-21 . Thus, it is crucial to understand the molecular mechanisms that limit the inflammatory response and establish the balance between TLR4-MyD88 signaling and TLR4-TRIF signaling.
T he host innate immune inflammatory response to lipopolysaccharide (LPS) from Gram-negative bacteria is mediated by the recognition of LPS by Toll-like receptor 4 (TLR4) in the context of TLR4-bound its co-receptor MD2 [1] [2] [3] . TLR4 is unique among the TLRs in that following the recognition of LPS by MD2, two separate 'modes' of signaling can be initiated, each from a distinct cellular compartment that utilizes distinct signaling intermediates, which results in discrete transcriptional programs 4 . Cell-surface TLR4 engages the intracellular adaptors TIRAP (Mal) and MyD88 through interactions with its Toll-interleukin 1 (IL-1) receptor (TIR) domain to activate signaling via the transcription factor NF-κ B and kinases of the MAPK family and subsequent transcription of genes encoding proinflammatory cytokines (e.g., Tnf and Il1b) 5 . A qualitatively distinct signal-transduction cascade is elicited following endosomal translocation of a portion of LPS-bound TLR4-MD2 through an incompletely understood action of the cell-surface co-receptor CD14 [6] [7] [8] . The TIR domain of endosomal TLR4 engages the adaptor TRAM, which recruits the adaptor TRIF and leads to activation of the kinase TBK1 that leads to phosphorylation of the transcription factor IRF3 and, ultimately, the production of type I interferons (e.g., IFN-β ) [9] [10] [11] [12] . In addition, TRIF signaling also activates a second, unique pathway that involves caspase-8 and the kinases RIP1 and RIP3, which leads to caspase-1-independent processing of pro-IL-1β [13] [14] [15] . The kinetics of activation and termination of the separate signal-transduction cascades driven by MyD88 and TRIF are necessarily limited to protect host tissues from excessive inflammation and to re-establish homeostasis. While MyD88-dependent production of cytokines is crucial for the clearance of many bacterial infections 16 , conversely, the production of type I interferons can promote infection in various models by a mechanism that involves a poorly understood immunosuppression [17] [18] [19] [20] [21] . Thus, it is crucial to understand the molecular mechanisms that limit the inflammatory response and establish the balance between TLR4-MyD88 signaling and TLR4-TRIF signaling.
Detailed understanding exists of how the kinetics of MyD88dependent signaling are regulated. MyD88-driven NF-κ B rapidly drives expression of the enzyme A20 that accumulates and causes disassembly of the NF-κ B and MAPK signalosomes through deubquitinase activities as well as ubiquitin-ligase activities 22, 23 . The negative feedback loop mediated by the induction of A20 is critical for host homeostasis, as A20-deficient mice succumb to massive inflammation shortly after birth and A20-deficient macrophages display prolonged MyD88 signaling with enhanced NF-κ B and MAPK responses 24 . Notably, however, macrophages deficient in A20 display normal regulation of LPS-driven activation of IRF3, which indicates that a distinct feedback loop regulates the TLR4-TRIF pathway 24 .
Endogenously produced prostaglandin E 2 (PGE 2 ) is a strong candidate for the inhibition of TLR4-dependent production of interferons due to its rapid synthesis and secretion in response to LPS 25, 26 and its autocrine mode of action 27 , as well as its noted immunomodulatory ability during infection with Gram-negative bacteria 28 . Additionally, PGE 2 has also been shown to display a reciprocally antagonistic pattern of expression with IFN-α and IFN-β in some models of bacterial infection 29 . PGE 2 itself is a secreted, bioactive, signaling lipid that frequently acts in an autocrine-paracrine manner that can influence both inflammatory processes and homeostatic processes 30, 31 .
In search of possible endogenous regulatory circuits that limit IFN-β production dependent on TLR4-TRIF during the response to LPS from Gram-negative bacteria, we performed a microarray analysis to identify genes expressed differentially in wild-type primary mouse thioglycollate-elicited peritoneal macrophages (TEPMs) infected with Salmonella enteritidis serovar Typhimurium (ST) relative to the expression of those genes in their IFN-β -deficient (Ifnb -/-) counterparts. Subsequent bioinformatics analysis of those data predicted transcriptional regulators whose activities were inversely related to IFN-β expression during ST infection and Articles NATuRE IMMuNoLoGy identified the high-affinity PGE 2 -specific receptor EP4 (encoded by Ptger4). We report here that in response to bacterial LPS, PGE 2 was rapidly released from mouse macrophages and participated in an autocrine-paracrine regulatory loop through EP4. This PGE 2 -EP4 signaling axis specifically limited the TRIF-dependent arm of the TLR4 response to LPS and thereby reduced the production of type I interferons, as well as the TRIF-dependent, caspase-1-independent processing of IL-1β . These findings contribute to the understanding of the regulation of endosomal TLR4 signals, as well as how the production of type I interferons during bacterial infection might be limited by the host.
Results
LPS-dependent PGE 2 limits IFN-β production. We initially carried out a microarray analysis to identify transcripts whose induction by ST infection in macrophages was increased or inhibited specifically by IFN-β expression (wild-type versus Ifnb -/-). With these data, we used the Upstream Regulator Analytic tool of Ingenuity Pathway Assist software to identify transcriptional regulators whose activity was predicted to be elevated or inhibited by IFN-β during the response to ST. As expected, this analysis identified various known regulators of the production or signaling of type I interferons as being inhibited in the absence of IFN-β expression ( Fig. 1a ). Notably, this analysis also indicated that the PGE 2 -specific receptor EP4 displayed activity inversely related to the production of IFN-β during the early (6-hour) inflammatory response to ST infection, a time point at which the innate inflammatory response to ST is predominantly TLR4 dependent 17 .
To elucidate a possible role for autocrine or paracrine PGE 2 in the regulation of TLR4 signaling in response to LPS, we first determined the kinetics of endogenous PGE 2 production in LPSstimulated peritoneal macrophages. Activation of the proximal enzyme in the PGE 2 biosynthetic cascade, the calcium-dependent phospholipase cPLA2, was assessed by phosphorylation-specific immunoblot analysis. Stimulation of mouse peritoneal macrophages with LPS resulted in activation of cPLA2 within 30 min that ended by 90 min (Fig. 1b ). Quantitation of extracellular PGE 2 by ELISA indicated that secreted PGE 2 was readily detected within 3 h of LPS stimulation and that LPS-dependent release of PGE 2 was inhibited by a small-molecule antagonist of the microsomal PGE 2 synthase mPGES, the terminal enzyme in the PGE 2 biosynthetic cascade that is essential for LPS-induced production of PGE 2 (ref. 32 ) ( Fig. 1c ). Analysis of the concentration of secreted cytokines in supernatants of LPS-stimulated macrophages treated with vehicle (DMSO) or the mPGES antagonist revealed no effect of the inhibition of PGE 2 on production of the cytokine TNF; however, inhibition of the production of PGE 2 resulted in an increase in the secretion of IFN-β ( Fig.  1d ). This result was consistent with our preliminary hypothesis that autocrine-paracrine PGE 2 might negatively regulate the TLR4activated TRIF signaling pathway. Extracellular PGE 2 can be sensed by any of four specific PGE 2 receptors, EP1-EP4, each of which has distinct expression patterns and functions 33 . We initially focused on a role for EP4, as it was identified in our bioinformatics analysis and had previously been linked to the regulation of innate inflammatory responses 34 . Therefore, macrophages were stimulated with LPS in the presence or absence of a specific, high-affinity antagonist of EP4. Treatment of cells with this EP4 antagonist produced results identical to those obtained with the mPGES antagonist in terms of enhanced production of IFN-β with no effect on TNF secretion ( Fig. 1e ). Analysis of additional, non-secreted proteins dependent on MyD88 (i.e., A20) or IFN-β (i.e., PKR) confirmed this pattern of regulation ( Supplementary Fig. 1 ). In contrast to the increased production of IFN-β seen in LPS-stimulated macrophages treated with the EP4 antagonist, no enhancement of LPS-induced IFN-β was observed in the presence of specific antagonists of other PGE 2 receptors (EP2 or EP3) ( Fig. 1f ). To determine if inhibiting the sens-ing of PGE 2 by EP4 regulated Ifnb transcription, we measured Tnf and Ifnb mRNA over a 6-hour time course of LPS stimulation without or with the EP4 antagonist. Selective blockade of EP4 enhanced transcription of LPS-induced Ifnb mRNA but not that of Tnf mRNA ( Fig. 1g ). To confirm the role of EP4 in regulating LPS-induced IFN-β , we generated bone marrow-derived macrophages (BMDMs) from wild-type and Ptger4 -/-(EP4-null) mice and compared their production of LPS-induced IFN-β protein. Ptger4 -/-BMDMs produced substantially more IFN-β than did wild-type BMDMs (Fig.  1h ). These data indicated a role for endogenously produced PGE 2 in the selective suppression of IFN-β production in response to LPS.
Inhibition of PGE 2 -EP4 enhances the activation of IRF3. To explore the mechanism underlying the selective suppression of the production of IFN-β by PGE 2 -EP4 during the response to LPS, we assessed activation of the TRIF-activated transcription factor IRF3 over a 180-minute time course. In vehicle-treated, LPS-stimulated macrophages, activation of IRF3 (assessed as phosphorylated IRF3) was observed between 60 min and 120 min after stimulation, in agreement with published work 35 . However, in the presence of the EP4-specific antagonist, we observed enhanced amplitude and duration of the activation of IRF3 ( Fig. 2a ). In the presence of the EP4 antagonist, enhanced LPS-dependent activation of IRF3 was also observed in the human monocytic cell line THP-1 and in primary human monocytes ( Supplementary Fig. 2 ). To determine the extent to which antagonism of EP4 might prolong the activation of IRF3, we extended the time course of LPS stimulation and observed substantial phosphorylation of IRF3 as late as 5 h after stimulation with LPS in the presence of the EP4 antagonist ( Fig. 2b) .
To determine the specificity of EP4's regulation of IRF3, we assessed the LPS-dependent activation of MAPKs in the presence or absence of the EP4 antagonist. We found no modulation of activation of the MAPKs Jnk, Erk or p38 in LPS-stimulated macrophages by the EP4 antagonist ( Fig. 2c ). Thus, the inhibitory effect of the PGE 2 -EP4 signaling axis seemed to be specific for TLR4mediated signaling via TRIF.
We additionally assessed the effect of EP4 antagonism on degradation of the inhibitory cytoplasmic NF-κ B chaperone Iκ Bα in response to LPS. The early kinetics of the degradation of Iκ Bα were not affected by antagonism of EP4; however, we consistently observed a delay in the re-synthesis of Iκ Bα in the presence of the inhibitor of EP4 ( Fig. 2d ). This delayed re-synthesis of Iκ Bα was consistent with the results of a published report demonstrating regulation of the re-synthesis of Iκ Bα by the TRIF pathway 36 . To confirm the results obtained with the EP4 antagonist, we compared the time course with which IRF3 was activated in wildtype BMDMs versus that in Ptger4 -/-BMDMs. Consistent with the results of our inhibitor studies, the activation of IRF3 was extended in the LPS-stimulated Ptger4 -/-BMDMs ( Fig. 2e ). The specificity of EP4 in regulating the activation of IRF3 was confirmed by comparison of the effects of the EP4 antagonist with those of the EP2-or EP3-specific antagonists. Only inhibition of EP4 enhanced and prolonged the LPS-dependent activation of IRF3 ( Fig. 2f ). To control for potential nonspecific effects of our EP4 antagonist, we subsequently compared the effects of global inhibition of PGE 2 by the mPGES antagonist on the activation of IRF3 ( Fig. 2g ) and its effects on the re-synthesis of Iκ Bα (Fig. 2h ). In both instances, inhibiting the production of PGE 2 globally recapitulated the effects of the EP4-specific antagonist. Finally, we sought to ascertain if it were possible to amplify the effects of the endogenous autocrine or paracrine PGE 2 regulatory loop by treating macrophage cultures with exogenous PGE 2 . The addition of 1 μ M PGE 2 to macrophage cultures, concurrent with LPS stimulation, substantially suppressed the activation of IRF3 (Fig. 2i) . These experiments indicated that endogenously produced PGE 2 regulated TLR4-dependent transcription of Ifnb by limiting the activation of IRF3.
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NATuRE IMMuNoLoGy PGE 2 -EP4 regulates the activation of TRIF. The considerable effect of EP4 antagonism on the TLR4-dependent activation of IRF3, an event known to be strictly dependent on the adaptor TRIF 10 , led us to speculate that PGE 2 -EP4 might be targeting this adaptor pathway specifically. LPS-induced activation of IRF3 was assessed in wild-type and TRIF-deficient (Trif -/-) peritoneal macrophages in the presence or absence of antagonists of mPGES or EP4. The activation of IRF3 following stimulation with LPS was strictly TRIF dependent, whether or not the mPGES antagonist was present ( Fig. 3a) . Notably, the effect of the mPGES and EP4 antagonists on LPS-induced re-synthesis of Iκ Bα was completely reversed in Trif -/macrophages ( Fig. 3a) , again in support of the notion that the PGE 2 -EP4 axis specifically targeted the TRIF signaling pathway in its regulation of TLR4 signaling.
The TRIF pathway is initiated by the CD14-dependent translocation of the TLR4-LPS-MD2 complex to an endosome, where it recruits the adaptors TRAM and TRIF to the TLR4 TIR domain that is exposed to the cytosol 6 . We monitored the endosomal translocation of TLR4 by cell-surface staining of TLR4 and flow cytometry. Unstimulated cells exhibited no internalization of TLR4 over the time monitored. However, either antagonizing EP4 with the EP4 antagonist ( Fig. 3b ) or treating macrophages with the mPGES antagonist ( Supplementary Fig. 3 ) resulted in faster and greater LPS-induced loss of TLR4 from the cell surface than that of vehicletreated (control) macrophages.
Little is known of the signaling determinants that permit CD14dependent translocation of TLR4 to endosomes, but it has been shown that there is an absolute requirement for activation of the tyrosine kinase Syk in a CD14-dependent, but TLR4-independent, fashion 7 . Therefore, LPS-induced activation of Syk was assessed in the presence or absence of the EP4 antagonist. Antagonism of EP4 during stimulation with LPS resulted in more-rapid and increased activation of Syk ( Fig. 3c ), consistent with the results of our TLR4internalization experiments (Fig. 3b ). To further assess the hypothesis that PGE 2 -EP4 feedback restricts TRIF signaling specifically, we stimulated peritoneal macrophages with Pam3Cys, a ligand for TLR2, which is a TLR that engages MyD88 but not TRIF. Addition of the mPGES antagonist did not affect TLR2-dependent signaling or result in TLR2-dependent activation of IRF3 ( Fig. 3d ). We did not, however, observe an effect of the EP4 antagonist on the induction of IFN-β in response to stimulation of TLR3 by its ligand poly(I:C), probably due to the fact that poly(I:C) was a much weaker inducer of the release of PGE 2 than was LPS ( Supplementary Fig. 4) . These experiments demonstrated that PGE 2 regulated activation of the TLR4-TRIF pathway through trafficking and that TRIF expression was required for the regulation of TLR4 signaling by PGE 2 .
PGE 2 -EP4 restricts TRIF-dependent activation of caspase-8.
While feedback by PGE 2 through EP4 is capable of restricting TLR4-TRIF-dependent activation of the TBK1-IRF3 pathway, the TLR4-TRIF complex is also capable of activating caspase-8, which leads to limited processing of IL-1β . To determine whether that second TRIF-dependent pathway was sensitive to PGE 2 , we assessed the effect of the EP4 antagonist on LPS-dependent activation of IRF3, in LPS-stimulated wild-type macrophages relative to that in Trif -/macrophages ( Fig. 4a ). It has been reported that the stimulation of macrophages with LPS alone results in low-level process- 
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ing and release of mature IL-1β in a manner that is dependent on TRIF and caspase-8 and is independent of caspase-1 13, 15 . We speculated that release of PGE 2 might limit this TRIF-caspase-8-dependent effect on IL-1β . Antagonizing EP4 significantly enhanced the LPS-dependent release of IL-1β in a TRIF-dependent fashion and in the absence of a second inflammasome-activating stimulus (Fig.  4b ). Because activation of EP4 by exogenous PGE 2 has been shown to inhibit inflammasome NLRP3-dependent activation of caspase-1 and processing of IL-1β in response to activators of LPS and NLRP3 34 , we assessed caspase-1 directly but found no activation due to the presence of the EP4 antagonist (Fig. 4c) . These results demonstrated that both of the known signal-transduction pathways initiated by TLR4-TRIF were negatively regulated by PGE 2 .
cAMP-dependent effector molecules are regulators of TRIF.
Having established that signaling through the receptor EP4 was required for the restriction of TRIF-dependent signals downstream of TLR4, we sought to define EP4-activated pathways necessary for this effect. There are two well-defined G protein-activated signaltransduction cascades downstream of EP4; the first leads to activation of phosphatidylinositol-3-OH kinase (PI(3)K) and the kinase Akt, and the second activates an endogenous adenylate cyclase (AC) that leads to accumulation of cAMP and activation of the cAMPdependent effector molecules PKA (a kinase) and EPAC (the nucleotide-exchange factor for small GTPases) 37 (Fig. 5a ). While complete inhibition of basal and LPS-inducible phosphorylation of Akt was achieved with the Akt antagonist, that antagonist had no effect on the LPS-dependent activation of IRF3 (Fig. 5b) . In contrast, inhibition of either of the cAMP-dependent effector molecules (PKA or EPAC) led to an increase in the LPS-dependent activation of IRF3 ( Fig. 5c,d) , which suggested that the AC-dependent pathway mediated EP4's effects. To assess directly the ability of cAMP to suppress TLR4-dependent activation of IRF3, we used recombinant AC toxin from Bordetella pertussis, which rapidly catalyzes the production of cytosolic cAMP independently of host enzymes 38 . The addition of B. pertussis AC toxin reduced the TLR4-mediated activation of IRF3 in a dose-dependent way (Fig. 5e ), in addition to slowing the kinetics with which TLR4 was internalized (Fig. 5f) . Thus, the inhibitory effects of EP4 on the TLR4-TRIF pathway were mediated by cAMPdependent effector molecules.
PGE 2 -EP4 regulates infection in vitro and in vivo.
To determine whether the observed PGE 2 -EP4 feedback might be important in restricting the activation of IRF3 during in vitro infection with live Gram-negative pathogens, we infected peritoneal macrophages with intracellular ST at a low multiplicity of infection (MOI) of 4 in the presence or absence of the mPGES inhibitor and assessed activation of IRF3 6 h later. In the absence of the mPGES inhibitor, no detectable activation of IRF3 was observed after infection with ST (Fig. 6a ). Inhibition of PGE 2 synthesis, however, substantially increased the activation of IRF3 in response to ST in vitro ( Fig.  6a) . ST is an intracellular pathogen and presumably presents LPS to TLR4 during the entire course of infection. Therefore, we sought to determine whether EP4 was also active in restricting the activation of IRF3 following 60 min of incubation of macrophages with either of two extracellular, enteric Escherichia coli strains (enterohemorrhagic E. coli or enteropathogenic E. coli) or the mouse extracellular enteric pathogen Citrobacter rodentium (MOI = 25). As observed for ST, restriction of the production of PGE 2 by inhibition of mPGES enhanced the activation of IRF3 following infection with enteropathogenic E. coli, enterohemorrhagic E. coli or C. rodentium (Fig. 6b ).
To confirm that the PGE 2 -EP4 axis limited the production of type I interferons during in vivo infection with a Gram-negative pathogen, we pre-treated C57BL/6 J mice with a single intraperitoneal injection of saline or EP4 antagonist (50 μ g per mouse) 60 min before intraperitoneal infection of the mice with ST. At 8 h after infection, mice were euthanized and the spleen and liver were harvested for gene-expression analysis. Mice that received the EP4 antagonist displayed significantly higher Ifnb expression in the spleen than that of saline-treated mice (Fig. 6c) , with a similar trend observed in the liver (data not shown). Consistent with our in vitro studies, the effects of the EP4 antagonist displayed gene specificity and did not alter the in vivo expression of Tnf, but we did observe reduced expression of Il1b mRNA (Fig. 6c ), in agreement with a published report on a role for PGE 2 in Il1b transcription 39 . Analysis of ST colony-forming units in the spleen did not show substantially altered numbers of this bacteria in either group at this early time point (Fig. 6d) . These results indicated that signaling via the PGE 2 -EP4 axis was important in limiting the activation of IRF3 and induction of IFN-β during infection with Gram negative bacteria in 
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vitro and in vivo. The expression of type I interferons during in vivo ST infection can promote pathogenesis and increase mortality in mice 17, 18, 40, 41 . We therefore hypothesized that in vivo administration of EP4 antagonists during systemic infection with ST would result in increased mortality due, at least in part, to elevated production of IFN-β . To determine the effect of EP4 antagonism on the course of ST infection, we infected mice intraperitoneally with ST (1 × 10 3 colony-forming units), followed by twice-daily injection of the EP4 antagonist or saline (as a control). Mice that received the EP4 antagonist succumbed more rapidly to infection than did saline-treated mice (Fig. 6e ), consistent with a key role for PGE 2 -EP4 in the host defense against ST. Our data are consistent with a model in which PGE 2 is rapidly released in response to ligation of TLR4 by LPS and selectively suppresses TLR4-TRIF signal transduction by activating cAMP-dependent effector molecules to restrict endosomal translocation of TLR4 ( Supplementary Fig. 6 ).
Discussion
Mechanisms that restrict TLR4-dependent production of cytokines are critical for limiting inflammatory damage and speeding the return to host homeostasis. The unique cell biology of TLR4dependent signaling requires that feedback mechanisms be in place to restrict both signaling initiated at the cell surface (dependent on TIRAP (Mal) and MyD88) and endosomal signaling (dependent on TRAM and TRIF). While cell-surface signals dependent on TLR4-MyD88 that activate NF-κ B and MAPK are subject to negative regulation by an A20 feedback circuit, A20 does not limit the endosomal activation of IRF3 via TLR4 and TRIF 24 . A negative feedback loop that restricts the TRIF complex has not been generally described; however, there are reports of other mechanisms that limit aspects of TRIF activity. The deubiquitinase DUBA has been shown to act to inhibit the K63 ubiquitin ligase TRAF3, an activity that limits the TRIF-dependent activation of IRF3 specifically 42 . Additionally, it has been demonstrated that inflammasome activation of caspase-1 during some bacterial infections can cleave TRIF and thereby limit TRIF-dependent signaling 43 ; however, such a mechanism would be operative only in the presence of second signal to permit maturation of the inflammasome.
Our current observations are both novel and important because we have described for the first time, to our knowledge, the action of an autocrine or paracrine PGE 2 -dependent feedback loop downstream of the activation of TLR4 by LPS that limits both the amplitude and the duration of TRAM-TRIF-dependent signaling by restricting the CD14-dependent trafficking of TLR4-MD2 into 
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endosomes necessary for the recruitment of TRAM-TRIF to the cytosolic TIR domain. The biochemistry of PGE 2 makes it uniquely suited to serve in a feedback capacity to regulate TLR4 responses for two reasons. First, PGE 2 can be rapidly synthesized and released within minutes after ligation of TLR4, independently of de novo transcription and translation 25 . Second, PGE 2 is an autocrine-acting factor with an extremely short life-span in vivo of less than 30 s (ref. 44 ), which would permit secreted PGE 2 to restrict TRIF signaling in a cell-autonomous manner with limited systemic effects, unlike a relatively long-lived protein cytokine. While PGE 2 can be recognized by four distinct G protein-coupled receptors (EP1-EP4) 33 , we identified EP4 specifically as mediating the actions of secreted PGE 2 directed against the TRIF pathway, and published reports highlight a growing appreciation of the importance of EP4 in regulating inflammatory responses in vitro and in vivo 34, 45 . While EP4 shares the greatest sequence and signaling similarity (including activating AC) with the PGE 2 receptor EP2, EP4 has an affinity for PGE 2 that is about seven-to eight fold greater than that of EP2 46 , which possibly makes EP4 uniquely suited to sense and respond to the low autocrine or paracrine levels of PGE 2 secreted soon after ligation of TLR4. Notably, while some published in vitro studies have shown a broadly suppressive effect of PGE 2 on all TLR4-driven cytokine responses [47] [48] [49] , such studies have typically relied on relatively high levels of exogenously added PGE 2 that might simultaneously ligate multiple distinct receptors for PGE 2 and produce a regulatory outcome distinct from that produced by the autocrine or paracrine loop described here.
Our data also support the hypothesis that downstream of EP4, the activation of endogenous AC enzymes and generation of cAMP are important for the action of EP4 in restricting TRIF-mediated signaling. The identification of the cAMP-dependent effector molecules PKA and EPAC in limiting TRIF-dependent activation of IRF3 is intriguing, given the effects of EP4 on the internalization of TLR4. The movement of TLR4 from the cell surface to an early , enteropathogenic E. coli (EPEC) or C. rodentium (MOI = 25) for 60 min (above blots), followed by treatment gentamycin and the mPGES antagonist (or not) and culture as in a (above lanes). c, Expression of Ifnb, Tnf and Il1b in the spleen (presented here) and liver (data not shown) of wildtype C57BL6/J mice (n = 5) pre-treated by intraperitoneal injection of saline alone (Vehicle) or with the EP4 antagonist (50 μ g per mouse) (horizontal axis) 60 min before intraperitoneal infection with ST (1 × 10 8 per mouse), followed by analysis 8 h later; results were normalized to those of Hprt. *P = 0.0017 (Ifnb) or 0.023 (Il1b) (Student's two-tailed t-test). d, Quantification of viable bacteria (as colony-forming units (CFU)) in the spleen of mice infected and treated as in c, assessed at 8 h by homogenization, followed by serial dilution on streptomycin-containing LB agar plates. e, Survival of mice given a single dose of saline or EP4 antagonist (50 μ g per mouse) (key) 1 h before intraperitoneal infection with 1 × 10 3 ST, followed by twice-daily injection of saline or EP4 antagonist (50 μ g per mouse) each day (key). *P = 0.001 (one-sided Mantel-Cox test). Each symbol (c,d) represents an individual mouse; small horizontal lines indicate the mean ( ± s.e.m.). Data are from one experiment representative of four (a) or two (b) separate experiments (n = 4 (a) or n = 2 (b)) with similar results (a,b) or are from one experiment with n = 5 mice per group (c,d) or n = 10 mice per group (e).
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NATuRE IMMuNoLoGy endosome compartment is essential for the recruitment of TRIF and activation of IRF3. While cell-surface expression of CD14 is absolutely required for the internalization of TLR4 in response to LPS, whether the rate of such internalization is constant or is dynamic and subject to regulation has not been investigated. Our work represents the first report, to our knowledge, showing that the kinetics with which TLR4 is internalized are subject to regulation by the extracellular inflammatory milieu. In this context, it is also notable that poly(I:C), a ligand for TLR3, a receptor that does not require trafficking to engage TRIF and is not inhibited by the EP4 antagonist, elicited much less release of PGE 2 than did LPS. While few details are known about the molecular machinery that coordinates the trafficking of TLR4, TRAM and TRIF to endosomes, it is clear that small GTPases (specifically, Arf6 and Rab11a) are required for this 50, 51 . Both PKA and EPAC have been shown to negatively regulate endosomal trafficking by GTPases of the Rab family and Rab11a in response to cAMP-generating bacterial toxins [52] [53] [54] . In this context, PKA and EPAC have been shown to act synergistically, targeting different aspects of the Rabll-exocyst complex, and thereby limit the kinetics of early recycling endosomes 55 . Conceivably, a similar role for PKA and EPAC could operate in response to endogenously produced PGE 2 to limit assembly of the TLR4-TRIF complex. Further studies will be needed to elucidate the precise intermolecular interactions between the cAMP effector molecules and elements of the TLR4-TRIF pathway; however, a potential implication of this model is that the rate of CD14-dependent internalization of TLR4 might be responsive to and reflective of the local concentration of PGE 2 .
Our current work has important implications for understanding how the different modes of TLR4 signaling shape the outcome of bacterial infection. In vivo, establishing a balance between proinflammatory cytokines (TNF, IL-1β and IL-6) and type I interferons is important in pathogenesis. Inflammatory cytokines are clearly needed to restrict bacterial growth and, ultimately, to clear microbes 16 , while some coincident production of type I interferons can be beneficial by limiting damage due to systemic inflammation 56 . However, the production type I interferons must be carefully regulated, as it has been shown in various other bacterial infection models that the suppressive effects of type I interferons promote bacterial growth and exacerbate disease 17, 18, 21, 29, 41, 57, 58 . Therefore, striking a precise balance between outcomes dependent on TLR4-MyD88 and those dependent on TLR4-TRIF is probably key to the re-establishment of homeostasis. Our data support the concept that the PGE 2 -EP4 axis is an important conduit of cross-talk between the two signaling pathways.
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Methods Animals and cells. Animal work performed for this study complied with all applicable provisions of the Animal Welfare Act; US Government Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training; Public Health Services Policy on the Humane Care and Use of Laboratory Animals; and Guide for the Care and Use of Laboratory Animals (8th edition). The protocol for this work was approved by the Institutional Animal Care and Use Committee of the University of Maryland, School of Medicine. Primary thioglycollate-elicited peritoneal macrophages (TEPMs) were prepared as described previously 59 . In brief, 3 ml of 3% sterile thioglycollate (Remel) was injected intraperitoneally into 6-to 8-week-old wild-type C57BL/6 J mice (Jackson Laboratories). 4 d later, macrophages were harvested by peritoneal lavage with sterile saline. TRIF-null (Trif -/-) mice backcrossed onto a C57BL/6 J background (n ≥ 10) were bred in-house as described previously 60 . Femurs from Ptger4 -/-(EP4deficient) mice and their Ptger4 +/+ littermates 61, 62 were used to generate BMDMs as described previously 63 . The human THP-1 cells were plated at 2 × 10 6 cells per well and were treated with 100 nM phorbol 12-myristate 13 acetate (PMA) for 48 h, after which the cells were washed and the PMA was removed. Cells were allowed to 'rest' for an additional 24 h before LPS stimulation. Human monocytes were isolated from whole blood by counterflow centrifugal elutriation from PBMCs that were obtained from the blood of healthy human volunteers at the Department of Transfusion Medicine, National Institutes of Health (NIH; provided by L. Wahl, National Institute of Dental and Craniofacial Research, NIH). Elutriated monocytes were plated for 2 h in serum-free medium (DMEM plus 1% penicillinstreptomycin and 1% l-glutamine). Human AB-positive serum (2.5%; Gemini Bio-Products) was added after 2 h. Monocytes were allowed to 'rest' overnight before stimulation with LPS (100 ng/ml) without or with EP4 antagonist (50 μ M) (Tocris Bioscience).
Antibodies and reagents. Antibodies to cPLA2 (D49A7), phosphorylated cPLA2 (D4I2A), IRF3 (D83B9), phosphorylated IRF3(4D4G), phosphorylated TBK1 (D52C2), phosphorylated JNK (81E11), phosphorylated Erk1/2 (D13.14.4E), p38 (D13E1), phosphorylated p38 (D3F9), Iκ Bα (44D4 and 9242), Syk (2712), Syk phosphorylated at Tyr525 and Tyr526 (C87C1), Akt (11E7) and Akt phosphorylated at Ser473 (clone D9E) were obtained from Cell Signaling. Antibody to caspase-1 p20 (clone Casper-1; catalog number AG-20B-0042-C100) was obtained from Adipogen. Protein-free phenol-and water-extracted E. coli K235 LPS was prepared as described previously 64 . S-[2,3-Bis(palmitoyloxy)-(2-RS)-propyl]-N-palmitoyl-(R)-Cys-Ser-Lys 4 -OH (Pam3Cys) and polyinosinic:polycytidylic acid (poly(I:C)) (VacciGrade) were purchased from InvivoGen. Purified adenylate cyclase (AC) toxin from Bordetella pertussis was a gift from E. Hewlett (University of Virginia) and has been described previously 38 . The mPGES inhibitor CAY10526 was obtained from Cayman Chemical. PGE 2 , EP4 antagonist (BGC 20-1531), EP2 antagonist (PF-04418948), EP3 antagonist (L-798,106), AKT1&2 inhibitor (AKTi-1/2), PKA inhibitor (H89 dihydrochloride) and EPAC inhibitor (ESI 09) were obtained from Tocris Bioscience.
ELISA. The ELISA used to detect PGE 2 was purchased from ENZO and was used according to the manufacturers' instructions. The mouse IFN-β ELISA was performed as previously described 35 .
Bacterial strains and infection. Salmonella Typhimurium (ST) strain SL1344 was a gift from R. Ernst. Enterohemorrhagic E. coli (EHEC), serotype O157:H7, strain TUV93-0 (EDL933 ∆ stx), enteropathogenic E. coli (EPEC), serotype O127:H6, strain E2348/69, and Citrobacter rodentium strain ICC168 have been previously described [65] [66] [67] , and were provided by J. B. Kaper. In vitro infection of mouse peritoneal macrophages with ST was carried out as described previously 17 . In brief, a single colony of ST strain SL1344 was inoculated into 5 ml LB medium and was grown overnight at 37 °C with shaking. The following morning, an additional 10 ml of LB medium was inoculated with 200 μ l of the overnight culture and was incubated at 37 °C with shaking until the OD 600 reached 1.5. Then, 1 ml of culture was pelleted by centrifugation and re-suspended into 1 ml sterile PBS. A quantity amounting to 400 μ l bacterial suspension was mixed with 600 μ l sterile PBS to obtain a concentration of ~4 × 10 6 bacteria per 10 ml culture. An appropriate volume of this re-suspension was mixed with 37 °C antibiotic-free RPMI 1640 to obtain the desired MOI. Bacteria were added to macrophages in culture plates, and infections were synchronized by centrifugation for 5 min at 700 r.p.m. Infected cultures were incubated at 37 °C for 30 min, and the infection medium was removed and replaced with RPMI 1640 containing 50 μ g/ml gentamicin, followed by incubation for an additional 45 min at 37 °C to kill extracellular bacteria. Following gentamicin incubation, the medium was removed, the cultures were washed twice with sterile PBS and the medium was replaced with antibiotic-free RPMI 1640.
For in vitro infection with EHEC, EPEC or C. rodentium, TEPM monolayers (9 × 10 5 cells per well) were plated 24 h before infection. Bacteria were inoculated directly from glycerol stocks in 3 ml of L-broth medium and were grown overnight at 37 °C without shaking. Macrophage monolayers were infected with each of the strains in triplicate at an MOI of 25 (2.3 × 10 7 bacteria per well) in 1 ml RPMI 1640 medium containing 2% FBS. Control monolayers were given the addition of 1 ml medium only. The monolayers were incubated for 1 h at 37 °C in 7% CO 2 . The medium was then replaced with 1 ml of fresh medium containing 100 μ g/ml gentamycin and 10 μ M CAY10526 (for drug-treated samples), and cells were incubated for an additional 6 h.
For in vivo ST-infection experiments to measure cytokine expression, wildtype C57BL/6 J mice were pre-treated by intraperitoneal injection of saline or BGC201531 (50 μ g) and, after 60 min, mice were infected intraperitoneally as described previously 17 . ST-infected mice were killed 8 h later and the spleen and liver were harvested for gene-expression analysis. For in vivo ST lethality studies, mice were given a single intraperitoneal injection of BGC201531 (50 μ g) one hour before intraperitoneal infection with 1 × 10 3 ST. On each successive day, mice were given injection of BGC20-1531 (50 μ g) twice daily and were monitored for morbidity and mortality.
Macrophage stimulation. TEPMs or BMDMs were plated at 2 × 10 6 cells per well in 12-well plates and were allowed to 'rest' overnight. Macrophage cultures were pretreated for 30 min with vehicle or inhibitor, followed by stimulation with LPS (100 ng/ ml) or Pam3Cys (InvivoGen) (250 ng/ml) for the times indicated in the figures.
Measurement of macrophage viability.
Macrophage viability was assessed using the Cell Titer Glo 2 reagent from Promega, according to the manufacturer's instructions.
Immunoblot analysis. Whole-cell lysates from macrophage cultures were obtained by the addition of lysis buffer (20 mM HEPES, pH 6.8, 1.0% Triton X-100, 0.1% SDS, 150 mM NaCl, 10 mM NaF and 1 mM PMSF) and subsequent incubation at 4 °C. Cell lysates were separated by denaturing SDS-PAGE and subsequent transfer to PVDF membranes. Blots were incubated overnight in relevant primary antibodies (identified above) at 4 °C and were washed three times with PBS, and then were incubated with the appropriate HRP-conjugated secondary antibody (Jackson HRP anti-rabbit (catalog number 111-035-003) or Jackson HRP antimouse (catalog number 115-035-003i); Jackson Immunochemicals). Blots were developed following incubation in ECL PLUS Western Blotting Detection Reagent (Amersham Bioscience). Immunoblots were quantitated using Image J software (NIH), and the ratio of specific signal intensity to loading control for each lane is provided directly under each blot.
TLR4-internalization assay.
These experiments were carried out in sterile flowcytometry tubes (BD). TEPMs were allowed to 'rest' overnight, pre-treated with medium only, BGC 20-1531, CAY10526 or synthetic PGE 2 for 15 min. To stimulate TLR4 internalization, cells were treated with LPS (100 ng/mL) at 37 °C, with 5% CO 2 . Sample collection and staining were performed as previously described 7 , with minor modifications 68 . In brief, at 0, 30, 60 or 90 min after the addition of LPS, cells were rapidly cooled by the addition of two volumes of ice-cold FACS buffer (0.5% FBS plus 2.0 mM EDTA in PBS), were centrifuged (1200 rpm) in a prechilled centrifuge and were resuspended in ice-cold medium at 0.5 ml per 1 × 10 6 cells. Samples were stored on ice until the collection of the final time point. All subsequent steps were carried out on ice using ice-cold buffers and reagents. Cells were washed twice in FACS buffer, then were treated with anti-CD16/32 (Fcγ RIIblocking antibody (clone 93; catalog number 101302; BioLegend); 2.0 μ g per 1 × 10 6 cells) for 20 min and were stained with PE-conjugated anti-mouse CD284 (anti-TLR4 (clone SA1521; catalog number 145403; BioLegend)); 0.4 μ g per 1 × 10 6 cells) or PE-conjugated rat IgG2a κ -chain isotype-matched control antibody (clone RTK 2758; catalog number 400507; BioLegend) for 30 min in the dark. Cells were washed twice in FACS buffer, and results were 'read' within 30 min on a FACSCanto II Flow Cytometer (BD) using FACSDiva software (BD) in the University of Maryland Flow Cytometry Core Facility, Center for Innovative Biomedical Resources, with 1 × 10 4 single cell events collected per tube. To confirm the viability of cells after flow cytometry, a sample of the cells remaining after completion of flow cytometry was stained with 0.2% trypan blue solution (Sigma), and live and total cell counts were determined by counting of unstained cells and all cells, respectively, using a standard hemocytometer (Reichert). Graphing and statistical analysis of FCS3 files was carried out in FCS Express 6 Plus (DeNovo Software). Data are presented as the average mean fluorescence intensity at each time point.
Caspase-1-and caspase-8-activation assays.
To measure caspase-1 activation, TEPMs were plated at 2 × 10 6 per well in 12-well plates. Cells were then treated with vehicle or EP4 antagonist (50 μ M) for 30 min, followed by LPS (100 ng/ml) for 3 or 6 h. For positive control conditions, 5 mM ATP (Sigma Aldrich) was added to cultures for the final 30 min. Whole-cell lysates were probed with antibody to caspase-1 (identified above). For caspase-8 activation, macrophages were pre-treated with inhibitors for 30 min before stimulation with LPS for the times indicated in the figures. Whole-cell lysates were probed with antibody to caspase-8 p55 (identified above; Enzo) or p18 (identified above; Cell Signaling). 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data analysis
The Transcriptional Regulator Analytic within the Ingenuity Pathway Analysis (IPA) software (Qiagen) current release was used to analyze microarray data. Prism V. 5 software for Mac was used in statistical analyses. Image J (NIH) v.1.52 was used to quantify immunoblots. FCS express v.6 software (DeNovo) was used in analysis of TLR4 internalization data.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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April 2018 principles). Caspase 1 antibody has been verified for specificity by manufacturer using knockout cell lines https://adipogen.com/ ag-20b-0042-anti-caspase-1-p20-mouse-mab-casper-1.html. Caspase-8 p55 antibody has been validated by manufacturer in wild-type and caspase 8 knockout cell lines http://www.enzolifesciences.com/ALX-804-447/caspase-8-mouse-monoclonalantibody-1g12/ 
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